Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
Brent A. Neuschwander‐Tetri(Saint Louis University), Rohit Loomba(University of California, San Diego), Arun J. Sanyal(Virginia Commonwealth University), Joel E. Lavine(Columbia University), Mark L. Van Natta(Johns Hopkins University), Manal F. Abdelmalek(Duke University), Naga Chalasani(Indiana University – Purdue University Indianapolis), Srinivasan Dasarathy(Case Western Reserve University), Anna Mae Diehl(Duke University), Bilal Hameed(University of California, San Francisco), Kris V. Kowdley(Virginia Mason Medical Center), Arthur J. McCullough(Cleveland Clinic), Norah A. Terrault(University of California, San Francisco), Jeanne M. Clark(Johns Hopkins University), James Tonascia(Johns Hopkins University), Elizabeth M. Brunt(Washington University in St. Louis), David E. Kleiner(National Cancer Institute), Edward Doo(National Institute of Diabetes and Digestive and Kidney Diseases)
Cited by 2,177